Iowanews Headlines

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s EGFR Inhibitors-induced Skin Disorders Market Insight, Epidemiology, and Market Forecast—2036.” This comprehensive report provides an in-depth understanding of EGFR Inhibitors-induced Skin Disorders, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the EGFR Inhibitors-induced Skin Disorders Market

• The market size for EGFR Inhibitors-induced Skin Disorders in the 7MM is expected to grow steadily by 2036.

• The United States holds the largest patient share of EGFR Inhibitors-induced Skin Disorders among the 7MM in 2025.

• Among EU4 and the UK, Germany accounted for the highest cases of EGFR Inhibitors-induced Skin Disorders in 2025, followed by France and Spain.

• According to Amaris et al. (2020), about 50–90% of patients treated with EGFR inhibitors develop a follicular or acneiform rash, negatively impacting quality of life.

• As per Guggina et al. (2017), cutaneous complications are the most frequent adverse effects of EGFR inhibitors, occurring in up to 90% of patients treated with cetuximab therapy.

• Dermatologic toxicity of any grade occurs in most patients who receive anti-EGFR therapy, while approximately 10%–20% of patients experience Grade 3/4 toxicity.

• The major therapies in development for EGFR Inhibitors-induced Skin Disorders include LUT-014 (Lutris Pharma), HT-001 (Hoth Therapeutics), ATR-04 (Azitra), and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market

Key Factors Driving the EGFR Inhibitors-induced Skin Disorders Market

Increasing Use of EGFR-targeted Cancer Therapies:The growing utilization of EGFR inhibitors in cancers such as Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), pancreatic cancer, head and neck cancer, and breast cancer is significantly increasing the burden of treatment-associated skin toxicities.

High Disease Burden and Lack of Approved Therapies:Currently, there are no approved therapies specifically indicated for the treatment of EGFR inhibitor-related cutaneous toxicities. Existing management approaches mainly rely on off-label use of topical steroids, antibiotics, emollients, antihistamines, and systemic corticosteroids.

Growing Focus on Supportive Oncology Care:As anti-EGFR therapies continue to expand across multiple tumor types and treatment regimens, there is an increasing emphasis on proactive toxicity management to improve patient quality of life, treatment adherence, and continuation of anticancer therapies.

EGFR Inhibitors-induced Skin Disorders Competitive Landscape

Several EGFR Inhibitors-induced Skin Disorders therapies are currently under development, including LUT-014 (Lutris Pharma), HT-001 (Hoth Therapeutics), and ATR-04 (Azitra).

LUT-014 is a topical B-Raf inhibitor being evaluated for EGFR inhibitor-induced acneiform lesions. HT-001 is a topical formulation under investigation for mild-to-moderate rash and skin disorders associated with EGFR inhibitor therapy. ATR-04 is a live biotherapeutic product candidate developed to address EGFR inhibitor-associated skin toxicity through modulation of skin immunity and inflammation pathways.

Discover more about therapies set to grab major EGFR Inhibitors-induced Skin Disorders market share @ EGFR Inhibitors-induced Skin Disorders Treatment Landscape

Recent Developments in the EGFR Inhibitors-induced Skin Disorders Market

• In August 2025, Azitra announced dosing of the first patient in its Phase I/II clinical trial evaluating ATR04-484 for EGFR-associated rash.

• In July 2025, Lutris Pharma presented positive Phase II trial data demonstrating efficacy of LUT014 gel in treating acneiform rash associated with anti-EGFR cancer therapies at the ESMO Gastrointestinal Cancers Congress 2025.

• In April 2025, Lutris Pharma presented new data from its clinical trial of LUT014 gel at the AACR Annual Meeting 2025.

• In September 2025, Hoth Therapeutics announced submission of a clinical trial application to the European Medicines Agency to expand its ongoing Phase II trial of HT-001.

• In June 2025, Hoth Therapeutics presented interim results from the Phase IIa CLEER-001 trial of HT-001 highlighting preservation of cancer treatment while resolving dermatologic side effects.

• In May 2025, Azitra presented posters describing the Phase I/II clinical trial of ATR04-484 at both the American Society of Clinical Oncology Annual Meeting and the American Society of Gene and Cell Therapy Annual Meeting.

What are EGFR Inhibitors-induced Skin Disorders?

EGFR Inhibitors-induced Skin Disorders are dermatologic toxicities caused by therapies targeting the Epidermal Growth Factor Receptor (EGFR). Common manifestations include acneiform rash, xerosis, pruritus, eczema, paronychia, and hair abnormalities. These skin toxicities can significantly affect patient quality of life and often interfere with continuation of anticancer therapy.

Management strategies generally involve topical corticosteroids, antibiotics, moisturizers, antihistamines, and supportive care interventions. However, there remains a substantial unmet need for approved therapies specifically designed for EGFR inhibitor-induced skin disorders.

EGFR Inhibitors-induced Skin Disorders Epidemiology Segmentation

The EGFR Inhibitors-induced Skin Disorders epidemiology section provides insights into the historical and current patient pool and forecasted trends across the 7MM. The market report proffers epidemiological analysis for the study period 2022–2036 segmented into:

• Incident Cases of Indications Harboring EGFR Mutation in the 7MM

• Incident Cases of EGFR Mutation in Respective Indications in the 7MM

• Incident Cases of Treatable Population by EGFR Inhibitors in the 7MM

• Incident Cases of EGFR Inhibitor-induced Skin Disorders in the 7MM

Scope of the EGFR Inhibitors-induced Skin Disorders Market Report

• Therapeutic Assessment: Current and emerging therapies for EGFR Inhibitors-induced Skin Disorders

• EGFR Inhibitors-induced Skin Disorders Market Dynamics: Key Market Forecast Assumptions and Market Outlook

• Key Companies: Lutris Pharma, Hoth Therapeutics, Azitra, and others

• Key Therapies: LUT-014, HT-001, ATR-04, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

To know more about EGFR Inhibitors-induced Skin Disorders companies working in the treatment market, visit @ EGFR Inhibitors-induced Skin Disorders Clinical Trials and Therapeutic Assessment

Table of Contents

1. EGFR Inhibitors-induced Skin Disorders Market Report Introduction

2. Executive Summary of EGFR Inhibitors-induced Skin Disorders

3. Epidemiology and Market Methodology

4. EGFR Inhibitors-induced Skin Disorders Market Overview at a Glance

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Emerging Therapies

8. EGFR Inhibitors-induced Skin Disorders: 7MM Analysis

9. Market Outlook

10. Market Size by Therapies

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

15. Appendix

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services